Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

41.05 +0.02 (+0.05%)
Official Closing Price Updated: 4:10 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
The Secret to Finding the Next Amazon Is Hiding in Plain Sight
These innovators are disrupting massive industries with a customer-centric business strategy. 
Via The Motley Fool
Topics Retirement
Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma
Via Stocktwits
Topics Government
Six Stocks That Shocked Wall Street: Unpacking This Year's Surprise Market Winners
The year 2025 has unfolded with a compelling narrative of unexpected triumphs in the stock market, where several companies have defied conventional wisdom and analyst forecasts to emerge as significant... 
Via MarketMinute
Topics Artificial Intelligence Economy
How Is The Market Feeling About Hims & Hers Health?
 
Via Benzinga
Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened
Via Stocktwits
Not Nearly Enough People Are Talking About Chewy Stock
The company has multiple trends working in its favor. 
Via The Motley Fool
Topics Artificial Intelligence
3 Healthcare Stocks Using AI to Drive Growth
AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation 
Via MarketBeat
Topics Artificial Intelligence
Hims & Hers Powers YieldMax's Latest Options-Based Income ETF
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY). 
Via Benzinga
Topics ETFs
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool analysts take a look. 
Via The Motley Fool
1 Momentum Stock with Competitive Advantages and 2 We Find Risky
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
2 Volatile Stocks Worth Investigating and 1 That Underwhelm
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
I'm Downgrading Hims & Hers Stock
The fast-growing company is taking investors on a roller-coaster ride. 
Via The Motley Fool
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2% in the morning session after an insider filed to sell a substantial block of shares. 
Via StockStory
Nvidia Just Got Another Tailwind -- Why Groq's $6.9 Billion Valuation Proves AI Chips Are Still Hot
Nvidia's unquestioned scale and ecosystem make it a clear winner. 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
3 Big Short Interest Names with Bullish Setups
HIMS, DLO, and TEM combine high short interest with bullish chart setups, creating strong breakout potential as market momentum stays hot. 
Via MarketBeat
Topics Artificial Intelligence
Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
Hims & Hers Health posted 73% revenue growth and 31% more subscribers in Q2. With analyst targets hitting $68, is now the time to buy HIMS? 
Via MarketBeat
Topics Economy
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.5% in the morning session after investors focused on the company's strong growth prospects, which appeared to overshadow recent... 
Via StockStory
Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds
Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown. 
Via Benzinga
The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors.
Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting. 
Via Investor's Business Daily
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom. 
Via Benzinga
Topics ETFs
Hims & Hers Health's Options Frenzy: What You Need to Know
 
Via Benzinga
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now
These dividend payers cranked up their payouts over the past decade, and they could do it again. 
Via The Motley Fool
Wall Street Waits on the Fed, but Steel and Semaglutide Steal the Show
US markets closed slightly lower on Tuesday as investors waited for the Fed’s rate decision. Strong retail sales weren’t enough to lift the market, while several standout stock moves, from Steel... 
Via Chartmill
Topics Economy
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one... 
Via The Motley Fool
Topics Economy Stocks
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) sent the company a warning letter regarding “false or... 
Via StockStory
BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today
Via Stocktwits
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days. 
Via Benzinga
FDA Slams Hims & Hers With A Warning Letter. Investors Slam Hims Stock.
The company is best-known for its compounded weight-loss drugs. But those could be in trouble. 
Via Investor's Business Daily
Huge News for Hims & Hers Stock
Testosterone could be a huge growth market for Hims & Hers. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.